Oral bioavailability of clonidine in children

Peter Larsson1, Anders Nordlinder, Henrik T G Bergendahl

  • 1Department of Physiology & Pharmacology, Section of Anaesthesiology & Intensive Care, Karolinska Institutet, Stockholm, Sweden. peter.larsson@karolinska.se

Paediatric Anaesthesia
|August 26, 2010
PubMed

Insights

Oral clonidine bioavailability in children undergoing surgery is 55.4%, which is lower than in adults. Higher pediatric doses are needed for similar therapeutic effects.

Area of Science:

  • Pediatric Pharmacology
  • Anesthesiology
  • Pharmacokinetics

Background:

  • Oral clonidine is a common premedication for children.
  • Adult oral clonidine bioavailability ranges from 75-100%.
  • Bioavailability of oral clonidine in children was previously unknown.

Purpose of the Study:

  • To determine the oral bioavailability of clonidine in children.
  • To characterize the pharmacokinetic profile of oral clonidine in pediatric patients.

Main Methods:

  • Children aged 3-10 years received oral clonidine (4 mcg·kg(-1)) mixed with fruit drink.
  • Plasma clonidine concentrations were measured over 18 hours using liquid chromatography-mass spectroscopy.
  • Pharmacokinetic parameters were calculated using nonlinear mixed-effects models and pooled with existing IV clonidine data.

Main Results:

  • A two-compartment model described the time-concentration profiles.
  • Key pharmacokinetic parameters included absorption half-life (0.45 h) and lag time (0.148 h).
  • Oral bioavailability was determined to be 55.4% (95% CI 0.469-0.654).

Conclusions:

  • Oral clonidine absorption in children is variable and relatively slow (Tmax 1.04 h).
  • The oral bioavailability of 55.4% is significantly lower than in adults.
  • Higher oral clonidine doses (per kg) are necessary in children to achieve adult-like plasma concentrations.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Bioavailability: Overview01:13

Bioavailability: Overview

Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
Bioavailability: Overview01:17

Bioavailability: Overview

Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...